Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.47 |
| ▸ | AKT1 | P31749 | 4/20 | 0.41 |
| ▸ | AKT2 | P31751 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432433 | 0.89 | HDAC1 (0.46) | HDAC1AKT1AKT2HDAC8IDH1 | |
| SCHEMBL4432437 | 0.89 | HDAC1 (0.46) | HDAC1AKT1AKT2HDAC8IDH1 | |
| SCHEMBL974029 | 0.88 | HDAC1 (0.47) | HDAC1AKT1AKT2HDAC8IDH1 | |
| SCHEMBL974028 | 0.88 | HDAC1 (0.47) | HDAC1AKT1AKT2HDAC8IDH1 | |
| SCHEMBL12190633 | 0.85 | TTR (0.46) | HDAC1HDAC8 | |
| SCHEMBL6368019 | 0.81 | HDAC1 (0.41) | HDAC1AKT1AKT2HDAC8 | |
| SCHEMBL973372 | 0.79 | AKT1 (0.47) | HDAC1AKT1AKT2IDH1 | |
| SCHEMBL973374 | 0.79 | AKT1 (0.47) | HDAC1AKT1AKT2IDH1 | |
| SCHEMBL12190763 | 0.76 | TTR (0.46) | HDAC1AKT1 | |
| SCHEMBL13680346 | 0.76 | TTR (0.46) | HDAC1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | HDAC1 1089/4885AKT1 2142/4885AKT2 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.